Lymphoma treatment approved

I reported previously (3rd Sep) on the US takeover of Israeli biotech Kite for $12 billion. The US FDA has now approved Kite’s Yescarta treatment for adults with relapsed or refractory large B-cell lymphoma. The treatment uses Israeli-developed CAR-T therapy from the patient’s own T-cells.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *